TELA Bio, Inc.

TELA

NASDAQ

Healthcare

Medical - Devices

Malvern, PA, US209 employeestelabio.com

$0.60

+0.03(5.01%)

Mkt Cap $27M

$0.56

$2.14

52-Week Range

At a Glance

AI-generated

TELA Bio, Inc.

Revenue breakdown: Single Reportable Segment (100%).

8-K

TELA Bio, Inc. received a deficiency letter from Nasdaq on March 17, 2026, notifying that its common stock's closing bid price was below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The Company has 180 calendar days until September 14, 2026, to regain compliance by achieving $1.00+ closes for 10 consecutive business days, with no immediate effect on its Nasdaq Global Market listing.

$27M

Market Cap

$76M

Revenue

-$38M

Net Income

Employees209

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($208M)

Revenue by Geography

Non Us100%($29M)

Activity

What Changed Recently

Delisting

Mar 19, 2026

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2026, TELA Bio, Inc. (the “ Company ”) receive

Peer Companies

Company	Price	Change	Market Cap	P/E
EQEquillium, Inc.	$1.97	-3.43%	$70M	-3.0
SRTSSensus Healthcare, Inc.	$4.10	-2.38%	$67M	-8.7
MDAISpectral AI, Inc.	$1.46	+1.04%	$46M	-2.8
COEPCoeptis Therapeutics Hold...	$11.94	+5.85%	$42M	-3.9
SPRBSpruce Biosciences, Inc.	$71.00	+2.11%	$41M	-1.2
NRXPNRx Pharmaceuticals, Inc.	$2.20	+1.85%	$38M	-1.0
CTSOCytosorbents Corporation	$0.58	+5.13%	$36M	-4.0
ICCMIceCure Medical Ltd	$0.30	-0.76%	$21M	-3.1

Analyst View

Company Profile

CIK0001561921

ISINUS8723811084

CUSIP872381108

Phone484 320 2930

Address1 Great Valley Parkway, Malvern, PA, 19355, US

SEC EDGAR